Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2018 | Clinical trial data for TKIs in ALK-rearranged NSCLC

Silvia Novello, MD, PhD, of San Luigi Gonzaga University Hospital, Orbassano, Italy, discusses results from recent clinical trials exploring the efficacy of different tyrosine kinase inhibitors (TKIs) on ALK-rearranged non-small cell lung cancer (NSCLC) at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.